Clinical trials: Cemiplimab
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Trial name
- NCT06444880
- Testing
- Ubamatamab, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Primary Objectives: Phase 1 -To characterize the safety and tolerability of isatuximab in combination with cemiplimab in participants with relapsed and refractory classic Hodgkin's lymphoma (cHL), diffuse large B-cell lymphoma…
- Trial name
- NCT03769181
- Testing
- isatuximab SAR650984, cemiplimab REGN2810
- Where
- 20 sites in France, Italy and 5 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Cutaneous Toxicity From ICI Therapy
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to…
- Trial name
- NCT04898751
- Testing
- Immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 2,214 people
- Sponsor
- Johns Hopkins University
Cancer, Immune-related Adverse Event
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database.
- Conditions
- Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- EXIT (NCT05934214)
- Testing
- Immune checkpoint inhibitor
- Where
- 2 sites in France
- Volunteers
- 141,630 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by…
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8
- Trial name
- NCT06900595
- Testing
- Biospecimen Collection, Cabozantinib, Cemiplimab
- Where
- 81 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
- Trial name
- NCT07527325
- Testing
- Fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT05608291
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,564 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called…
- Trial name
- NCT05352672
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 210 sites in United States, Argentina and 22 more
- Volunteers
- 1,546 people
- Sponsor
- Regeneron Pharmaceuticals